AI-powered digital biology for protein therapeutics and antibody discovery
Aureka Biotechnologies develops AI-powered digital-biology systems for discovering protein therapeutics and antibody treatments. The Laguna Hills company combines high-throughput functional screening with AI-based therapeutic design. Its $100M Series B announced on August 11, 2026 was led by Granite Asia, with HighLight Capital and Matrix Partners China among the disclosed participants.
Biotechnology📍 Laguna Hills, CAFounded 2023
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Aureka Biotechnologies going public?
No. Aureka Biotechnologies is private and has not filed to go public. There is no S-1 on file.
What is Aureka Biotechnologies' valuation in 2026?
No confirmed valuation is on record for Aureka Biotechnologies. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Aureka Biotechnologies filed an S-1?
No public S-1 is on file for Aureka Biotechnologies.
Is Aureka Biotechnologies publicly traded — can you buy Aureka Biotechnologies stock?
No. Aureka Biotechnologies is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Aureka Biotechnologies on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Weian Zhao
Founded
2023
HQ
Laguna Hills, CA
Growth
$100M Series B to expand AI-native therapeutic discovery
Last Round
Series B — $100M (Aug 2026) · Lead: Granite Asia
IPO Status
private
Fundraising Status
Series B · $100M · 3 mo ago
private1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series B
$100M
Aug 2026
Granite Asia
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Aureka Biotechnologies — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-11-16. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-10
Open roles
4
via careers page
Product-build share
75%
engineering, research, product, design
Trajectory
steady
heavy product build — 75% of open roles are product-building functions (engineering/research/product) — 1 of 4 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Research Engineer / Scientist, LLM Post-TrainingHead of Antibody Engineering (Technology Platform)AI × Wet-Lab LoopPlatform Strategy
Counted from Aureka Biotechnologies's live job board as of 2026-11-21; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Weian ZhaoAlon Wellner
Investors
Granite Asia · HighLight Capital · Matrix Partners China
Products
AI-powered digital-biology platform for protein therapeutics
High-throughput antibody discovery and design platform
BiotechnologyAIDrug DiscoveryProtein TherapeuticsSeries B
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.